B
Bull
Bull · 25%SLS
$1.80
Scenario price
$13.210
-1.737 (-13.15%)At close
Loading chart…
- High
- 14.790
- Open
- 14.770
- VWAP
- 13.72
- Vol
- 9.83M
- Mkt Cap
- 65.84M
- Low
- 13.150
- Amount
- 134.77M
- EV/EBITDA, TTM
- 0.00
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
AI analysis of Sellas Life Sciences Group Inc (SLS)
buySellas Life Sciences Group Inc appears to be a good buy right now due to its strong year-to-date performance of +203.68% and a promising price target from analysts of up to $35, suggesting a potential upside of over 150%. The main risk is the company's ongoing losses, with a net income of -9,605,000 USD in Q2 2026, but the positive sentiment around its cancer vaccine trials could offset this risk.
Valuation Metrics
The current forward P/E ratio for Sellas Life Sciences Group Inc (SLS) is 0.00, compared to its 5-year average forward P/E of -3.02.
Alphio AI Price Scenarios for SLS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SLS
Events Timeline
News
8.508-31stocktwitsSellas Life Sciences' Drug GPS Poised for Major Impact
4.008-31stocktwitsIran Strikes US Forces, Oil Prices Surge Amid Geopolitical Tensions
8.508-27stocktwitsARK Optimistic About Personalized Cancer Vaccine Future
9.008-26stocktwitsSELLAS Life Sciences' SLS009 Slows Pancreatic Cancer Cells
9.508-26stocktwitsInvestors Eye Nvidia Earnings and Macro Data Releases
SLS FAQ — answered by Alphio AI
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Sellas Life Sciences Group Inc appears to be a good buy right now due to its strong year-to-date performance of +203.68% and a promising price target from analysts of up to $35, suggesting a potential upside of over 150%. The main risk is the company's ongoing losses, with a net income of -9,605,000 USD in Q2 2026, but the positive sentiment around its cancer vaccine trials could offset this risk.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.